NasdaqGM:VBLT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Vascular Biogenics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VBLT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.5%

VBLT

3.1%

US Biotechs

4.0%

US Market


1 Year Return

-6.1%

VBLT

24.3%

US Biotechs

4.9%

US Market

Return vs Industry: VBLT underperformed the US Biotechs industry which returned 24.2% over the past year.

Return vs Market: VBLT underperformed the US Market which returned 5% over the past year.


Shareholder returns

VBLTIndustryMarket
7 Day-2.5%3.1%4.0%
30 Day-3.1%7.3%1.3%
90 Day5.2%31.2%29.5%
1 Year-6.1%-6.1%25.5%24.3%7.2%4.9%
3 Year-72.9%-72.9%32.8%28.4%36.1%27.2%
5 Year-80.3%-80.3%0.04%-5.7%65.3%46.9%

Price Volatility Vs. Market

How volatile is Vascular Biogenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vascular Biogenics undervalued compared to its fair value and its price relative to the market?

1.41x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VBLT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VBLT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VBLT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: VBLT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VBLT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VBLT is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Vascular Biogenics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

11.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VBLT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VBLT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VBLT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VBLT's revenue is expected to decline over the next 3 years (-3.3% per year).

High Growth Revenue: VBLT's revenue is forecast to decline over the next 3 years (-3.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VBLT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Vascular Biogenics performed over the past 5 years?

-3.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VBLT is currently unprofitable.

Growing Profit Margin: VBLT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VBLT is unprofitable, and losses have increased over the past 5 years at a rate of -3.3% per year.

Accelerating Growth: Unable to compare VBLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VBLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: VBLT has a negative Return on Equity (-65.62%), as it is currently unprofitable.


Next Steps

Financial Health

How is Vascular Biogenics's financial position?


Financial Position Analysis

Short Term Liabilities: VBLT's short term assets ($32.6M) exceed its short term liabilities ($7.9M).

Long Term Liabilities: VBLT's short term assets ($32.6M) exceed its long term liabilities ($3.7M).


Debt to Equity History and Analysis

Debt Level: VBLT is debt free.

Reducing Debt: VBLT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VBLT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VBLT has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 0.9% each year.


Next Steps

Dividend

What is Vascular Biogenics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VBLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VBLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VBLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VBLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VBLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.5yrs

Average management tenure


CEO

Dror Harats (63yo)

20.5yrs

Tenure

US$3,070,000

Compensation

Prof. Dror Harats, MD, has been the Chief Executive Officer of Vascular Biogenics Ltd., since 2000. Prof. Harats founded VBL in 2000 based on many years of research in Atherosclerosis, Vascular Biology and ...


CEO Compensation Analysis

Compensation vs Market: Dror's total compensation ($USD893.19K) is above average for companies of similar size in the US market ($USD605.69K).

Compensation vs Earnings: Dror's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dror Harats
CEO & Director20.5yrsUS$3.07m1.43% $838.4k
Amos Ron
CFO & Company Secretary9.17yrsUS$1.47m0.50% $292.3k
Erez Feige
Vice President of Business Operations6.5yrsUS$1.29m0.32% $189.0k
Eyal Breitbart
Vice President of Research & Operations14.5yrsUS$1.50m0.36% $212.1k
Naamit Sher
Vice President of Drug Development & Regulatory Affairs14.5yrsUS$1.25m0.26% $153.7k
Ayelet Horn
General Counsel20.5yrsno data0.099% $58.1k
Deborah Scott
Managing Director of Financial Communicationsno datano datano data
Yael Cohen
Medical Director12.5yrsUS$982.00kno data

14.5yrs

Average Tenure

57yo

Average Age

Experienced Management: VBLT's management team is seasoned and experienced (14.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dror Harats
CEO & Director20.5yrsUS$3.07m1.43% $838.4k
Ruth Alon
Independent Non-Executive Director10.33yrsno data0.080% $46.9k
David Hastings
Independent Non-Executive Director2.5yrsno data0.078% $45.8k
Ruth Arnon
Independent Non-Executive Director12.92yrsno data0.18% $105.8k
Bennett Shapiro
Independent Non-Executive Chairman13.5yrsno data0.089% $52.3k
Susan Kelley
Independent Non-Executive Director & Head of Scientific Advisory Board0.42yrno data0.078% $45.8k
Patrick Wen
Member of Scientific Advisory Boardno datano datano data
Keith Bible
Member of Scientific Advisory Boardno datano datano data
Bonnie Goldman
Member of Scientific Advisory Boardno datano datano data
Andrew Brenner
Member of Scientific Advisory Boardno datano datano data

11.6yrs

Average Tenure

66.5yo

Average Age

Experienced Board: VBLT's board of directors are seasoned and experienced ( 11.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VBLT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.5%.


Top Shareholders

Company Information

Vascular Biogenics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vascular Biogenics Ltd.
  • Ticker: VBLT
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$58.468m
  • Shares outstanding: 47.90m
  • Website: https://www.vblrx.com

Number of Employees


Location

  • Vascular Biogenics Ltd.
  • 8 HaSatat Street
  • Modi’in
  • 78106
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VBLTNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDOct 2014

Biography

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi’in, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 23:59
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.